Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911759 | 0.98 | MAPT (0.44) | MAPTSMN1; SMN2CHRNA7POLBCHRNB2 | |
| Bromide SCHEMBL3874702 | 0.87 | MAPT (0.41) | MAPTSMN1; SMN2CHRNA7POLBCHRNB2 | |
| SCHEMBL2911826 | 0.85 | MAPT (0.42) | MAPTSMN1; SMN2CHRNA7POLBCHRNB2 | |
| SCHEMBL15367682 | 0.76 | CHRNA7 (0.43) | CHRNA7POLBCHRNB2CHRNA4MEN1 | |
| SCHEMBL18459295 | 0.74 | LMNA (0.51) | MAPTCHRNA7CHRNB2CHRNA4KMT2A | |
| SCHEMBL7776562 | 0.74 | MC4R (0.48) | SMN1; SMN2CHRNA7POLBCHRNB2CHRNA4 | |
| SCHEMBL7071428 | 0.70 | ALDH1A1 (0.48) | MAPTPOLBMEN1KMT2ALMNA | |
| SCHEMBL8403545 | 0.69 | POLB (0.61) | POLBKMT2ALMNATSHR | |
| SCHEMBL14621959 | 0.68 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRHTR1A | |
| Bromide SCHEMBL3874361 | 0.67 | CCR5 (0.43) | MAPTCHRNA7POLBCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579339-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-7407938-B2 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-05 | — | — | US | disclosed |
| US-7390790-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-24 | — | — | US | disclosed |
| US-20070043017-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2007-02-22 | — | — | US | disclosed |
| US-20070037787-A1 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2007-02-15 | — | — | US | disclosed |
| US-7176194-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060270613-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2006-11-30 | — | — | US | disclosed |
| US-20040082561-A1 | Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043017-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | MAPT 4812/4885SMN1; SMN2 4716/4885CHRNA7 4866/4885 |
| US-20040082561-A1 | Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | MAPT 4800/4885SMN1; SMN2 4669/4885CHRNA7 4868/4885 |
| US-20060270613-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | MAPT 4812/4885SMN1; SMN2 4716/4885CHRNA7 4866/4885 |
| US-20070037787-A1 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | HPD, FABP2, CYP2B6 | MAPT 4885/4885SMN1; SMN2 4677/4885CHRNA7 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.